<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-135220" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Apremilast</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Padda</surname>
            <given-names>Inderbir S.</given-names>
          </name>
          <aff>Richmond University Medical Center/Mount Sinai</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bhatt</surname>
            <given-names>Rajat</given-names>
          </name>
          <aff>Mahatma Gandhi Mission&#x02019;s Medical College</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Parmar</surname>
            <given-names>Mayur</given-names>
          </name>
          <aff>Nova Southeastern University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Inderbir Padda declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rajat Bhatt declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mayur Parmar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-135220.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Apremilast is FDA approved for treating psoriatic arthritis in adult patients with moderately to severely active disease, plaque psoriasis in adult patients who are candidates for phototherapy or systemic therapy, and adults with Behcet disease associated with oral ulcers. It is a small molecule phosphodiesterase 4 (PDE4) inhibitor. Apremilast is also used off-label for various dermatologic disorders that are unresponsive or ineffective to conventional therapy (systemic corticosteroids or immunosuppressive agents). This activity will highlight the mechanism of action, adverse event profile, and other key factors pertinent to interprofessional team members in managing patients with moderate to severe psoriatic arthritis unresponsive to first-line therapy, plaque psoriasis, and Behcet disease.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of apremilast.</p></list-item><list-item><p>Describe the potential adverse effects of apremilast.</p></list-item><list-item><p>Review the appropriate monitoring for patients receiving apremilast.</p></list-item><list-item><p>Summarize interprofessional team strategies for improving care coordination and communication to advance apremilast use in treating psoriatic arthritis, plaque psoriasis, and Behcet disease and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=135220&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=135220">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-135220.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Apremilast is classified as a small-molecule phosphodiesterase 4 (PDE4) inhibitor.<xref ref-type="bibr" rid="article-135220.r1">[1]</xref>&#x000a0;It is FDA approved for plaque psoriasis in adult patients that are candidates for phototherapy or systemic therapy and psoriatic arthritis in adult patients with moderately to severely active disease.<xref ref-type="bibr" rid="article-135220.r2">[2]</xref> It is the first and only FDA-approved oral medication for oral ulcers associated with Behcet disease.<xref ref-type="bibr" rid="article-135220.r3">[3]</xref>&#x000a0;Apremilast is also used off-label for various dermatologic diseases that are unresponsive or ineffective to conventional therapy (systemic corticosteroids or immunosuppressive agents). Dermatologic diseases include hidradenitis suppurativa (acne inversa), atopic dermatitis (eczema), and alopecia areata.<xref ref-type="bibr" rid="article-135220.r4">[4]</xref>&#x000a0;</p>
        <p>
<bold>FDA Approved Use</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Psoriatic arthritis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Plaque psoriasis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Oral ulcers associated with Behcet disease</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-135220.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Apremilast is a selective inhibitor of the enzyme phosphodiesterase 4 (PDE4),&#x000a0;hindering&#x000a0;the conversion of&#x000a0;cyclic adenosine monophosphate (cAMP) to AMP, further causing an intracellular accumulation of cyclic adenosine monophosphate (cAMP).<xref ref-type="bibr" rid="article-135220.r1">[1]</xref>&#x000a0;The inhibition of&#x000a0;PDE4 is selective on the innate immune response&#x000a0;causing&#x000a0;a reduction in the production of inflammatory mediators such as CX-CL9, CX-CL10, IFN-&#x003b3;, TNF-&#x003b1;, IL-2, IL-8, IL-12, and IL-23 and further decreasing the inflammatory response.<xref ref-type="bibr" rid="article-135220.r5">[5]</xref><xref ref-type="bibr" rid="article-135220.r2">[2]</xref>&#x000a0;</p>
        <p>The&#x000a0;diminished&#x000a0;inflammatory response by PDE4 inhibition is what is&#x000a0;reported&#x000a0;to confer a therapeutic benefit and clinical improvements in psoriatic arthritis, plaque psoriasis, and Behcet disease, although the specific mechanism of apremilast is not well defined.<xref ref-type="bibr" rid="article-135220.r6">[6]</xref>&#x000a0;Apremilast inhibitory effects on other&#x000a0;phosphodiesterases, receptors, or enzymes are insignificant.<xref ref-type="bibr" rid="article-135220.r7">[7]</xref></p>
      </sec>
      <sec id="article-135220.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Apremilast is available in tablet form for oral consumption in adults in 10 mg, 20 mg, and 30 mg dosage forms. Its use&#x000a0;for treatment in&#x000a0;children aged 0&#x000a0;to 17 years has not been studied, and no data on safety and efficacy has been reported.<xref ref-type="bibr" rid="article-135220.r2">[2]</xref></p>
        <p>The dosing schedule for treating Psoriasis, Psoriatic arthritis, and Behcet disease is started as a 5-day titration period, gradually increasing the apremilast dose over the first five days until the recommended dose is reached.<xref ref-type="bibr" rid="article-135220.r2">[2]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Day 1 - 10 mg in the morning once a day</p>
          </list-item>
          <list-item>
            <p>Day 2 - 10 mg in the morning and 10 mg in the evening</p>
          </list-item>
          <list-item>
            <p>Day 3 - 10 mg in the morning and 20 mg in the evening</p>
          </list-item>
          <list-item>
            <p>Day 4 - 20 mg in the morning and 20 mg in the evening</p>
          </list-item>
          <list-item>
            <p>Day 5 - 20 mg in the morning and 30 mg in the evening</p>
          </list-item>
          <list-item>
            <p>Day 6 - 30 mg twice daily moving forward</p>
          </list-item>
        </list>
        <p>During the apremilast treatment initiation, patients should be started on a 10 mg dosage, followed by gradual dosage titration by an increase of 10 mg daily for six days, reaching the optimal daily dosage of 30 mg twice daily by day 6. The titration schedule helps prevent unwanted gastrointestinal adverse effects (severe diarrhea, nausea, and vomiting) that may occur with the initial therapy during the first few weeks. If the patient has impaired renal&#x000a0;function&#x000a0;(CrCl &#x0003c;30 mL/min), the dosing is 10 mg on days 1 to 3 and 20 mg on days 4 and 5 [(titrate using morning doses only (skip evening doses)] with a maintenance dose of 30 mg once daily in the morning after that. If a dose is missed, the patient is advised to talk to the doctor and pharmacist about when to take the next dose. Apremilast may be taken with or without regard. However, it should not be crushed, chewed, or split.<xref ref-type="bibr" rid="article-135220.r2">[2]</xref></p>
      </sec>
      <sec id="article-135220.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Some of the reported adverse effects include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Diarrhea (8%&#x000a0;to 41%)</p>
          </list-item>
          <list-item>
            <p>Nausea (9%&#x000a0;to 19%)</p>
          </list-item>
          <list-item>
            <p>Headache (6%&#x000a0;to 14%)</p>
          </list-item>
          <list-item>
            <p>Upper respiratory tract infection (4%&#x000a0;to 12%)</p>
          </list-item>
          <list-item>
            <p>Vomiting (3%&#x000a0;to 9%)</p>
          </list-item>
          <list-item>
            <p>Nasopharyngitis (3%)</p>
          </list-item>
          <list-item>
            <p>Upper abdominal pain (2%&#x000a0;to 9%)</p>
          </list-item>
          <list-item>
            <p>Fatigue (3%)</p>
          </list-item>
          <list-item>
            <p>Dyspepsia (3%)</p>
          </list-item>
          <list-item>
            <p>Decreased appetite (3%)</p>
          </list-item>
          <list-item>
            <p>Weight loss (13%)</p>
          </list-item>
          <list-item>
            <p>Insomnia (2%)</p>
          </list-item>
          <list-item>
            <p>Back pain (2% - 8%)</p>
          </list-item>
          <list-item>
            <p>Migraine (2%)</p>
          </list-item>
          <list-item>
            <p>Frequent bowel movements (2%)</p>
          </list-item>
          <list-item>
            <p>Mood disorders and suicidal ideation (5%)</p>
          </list-item>
          <list-item>
            <p>Arthralgia (6%)<xref ref-type="bibr" rid="article-135220.r8">[8]</xref><xref ref-type="bibr" rid="article-135220.r2">[2]</xref></p>
          </list-item>
        </list>
        <p>The most frequently reported side effects of apremilast are gastrointestinal (diarrhea, nausea), transpiring during the first&#x000a0;fourteen days of initiating therapy and typically resolving within&#x000a0;twenty-eight&#x000a0;days.<xref ref-type="bibr" rid="article-135220.r9">[9]</xref><xref ref-type="bibr" rid="article-135220.r10">[10]</xref>&#x000a0;The onset of depression and suicidal ideations and behaviors were also reported during clinical trials and may occur while on therapy.<xref ref-type="bibr" rid="article-135220.r11">[11]</xref></p>
      </sec>
      <sec id="article-135220.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Subjects with established hypersensitivity to apremilast or any&#x000a0;elements of the agent's formulations are contraindicated to therapy with&#x000a0;apremilast. Reproductive studies conducted in animal models during pregnancy demonstrated an increased risk of fetal loss with apremilast therapy.&#x000a0;No reproductive studies with apremilast treatment during pregnancy in humans have been reported to date.<xref ref-type="bibr" rid="article-135220.r12">[12]</xref>&#x000a0;</p>
        <p>Women of reproductive potential are highly encouraged for pregnancy planning and prevention.<xref ref-type="bibr" rid="article-135220.r13">[13]</xref>&#x000a0;Contraception use during therapy with apremilast is recommended in child-bearing women.&#x000a0;Women who are breastfeeding are contraindicated to treatment.&#x000a0;The administration of live vaccinations&#x000a0;while being&#x000a0;treated with apremilast&#x000a0;is also contraindicated.<xref ref-type="bibr" rid="article-135220.r2">[2]</xref></p>
        <p>Apremilast is a selective immunosuppressant agent and is considered a class of immunomodulatory or immunosuppressive medications. As per rheumatology recommendations and guidelines, apremilast is advised to be held for one to two weeks following the administration of the COVID-19 vaccination, as it may reduce the vaccine's therapeutic efficacy.&#x000a0;</p>
      </sec>
      <sec id="article-135220.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Once apremilast treatment is initiated, patients should be monitored for the development of adverse gastrointestinal manifestations (severe diarrhea, nausea, or vomiting). Dose reduction or treatment interruption should be prompted in the event of severe diarrhea, nausea, or vomiting. Patients with an underlying psychiatric history managed with apremilast should be monitored closely and routinely, as treatment may increase the risk of depression and suicidal behaviors. Patients receiving apremilast treatment should also routinely have their weight monitored, as significant weight reductions may occur and require dose reduction or treatment interruption.<xref ref-type="bibr" rid="article-135220.r2">[2]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-135220.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Once consumed, the agent is metabolized hepatically by the cytochrome P450 (CYP) system, specifically the CYP3A4 enzyme, and possesses a terminal half-life of 6&#x000a0;to 9 hours. Although moderate to severe hepatic impairment do not require dosing adjustments, patients with underlying severe renal impairments characterized as CrCl less than 30 mL/min requires dosage adjustment. The agent is eliminated primarily by the kidneys and excreted in urine (58%) and feces (39%). Subjects with a CrCl greater than or equal to 30 mL/minute do not require dosing adjustments.</p>
        <p>The use of apremilast in sequence with potent CYP450 inducers (rifampin, phenytoin, phenobarbital) is not recommended as drug-drug reactions may occur further, causing alterations in drug plasma concentration. No clinically significant drug interactions were reported with CYP450 inhibitors (ketoconazole, methotrexate)e).<xref ref-type="bibr" rid="article-135220.r13">[13]</xref></p>
      </sec>
      <sec id="article-135220.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Apremilast is classified as a small-molecule phosphodiesterase 4 (PDE4) inhibitor. It is indicated for psoriatic arthritis in adult patients with moderately to severely active disease, plaque psoriasis in adult patients that are candidates for phototherapy or systemic therapy, and adults with oral ulcers associated with Behcet's disease. Managing patients with such ailments necessitates interprofessional communication and continuity of care from the healthcare team. The interprofessional healthcare team should include a primary care physician (PCP), a rheumatologist, a dermatologist, a physical therapist (PT), nursing staff, and a pharmacist. Open-ended communication among patients and providers and thorough clinical analysis by the healthcare team can lead to more precise and practical treatment strategies leading to improved patient outcomes. [Level 5]</p>
        <p>Patients being initiated on therapy with apremilast should be counseled thoroughly on the 5-day titration regime and the potential risk of gastrointestinal adverse effects.&#x000a0;Patients experiencing these effects should also be counseled that the effects can occur within the first 14 days of initiating therapy and typically&#x000a0;resolve within 28 days. Patients who experience severe diarrhea, nausea, or vomiting should have dosing adjustments&#x000a0;or discontinue their treatment. Patients&#x000a0;who develop severe diarrhea should be assessed&#x000a0;for complications such as volume depletion and hypotension and corrected promptly,&#x000a0;particularly in&#x000a0;elderly patients&#x000a0;receiving apremilast.</p>
        <p>Patients should also be advised of potential neuropsychiatric adverse effects such as depression and suicidal ideation or behavior while receiving therapy. Patients with an underlying psychiatric history considering apremilast should be consulted with their psychiatrist to determine the patient's baseline psychiatric health and with the specialist to determine&#x000a0;the benefits of&#x000a0;therapy.&#x000a0;Routine&#x000a0;psychiatric assessments should be done before and after&#x000a0;initiating treatment in such patient demographics. Patients should also be monitored by their prescribing clinician for&#x000a0;regular weight&#x000a0;checks and advised to report any significant weight decreases. In such an occurrence, dosing adjustments or treatment termination by the healthcare team should be prompted.</p>
        <p>The interprofessional team should also regularly review the latest guidelines on psoriatic arthritis, plaque psoriasis, and oral ulcers associated with Behcet disease. Patients with any known hypersensitivity to apremilast and its constituents are contraindicated for treatment. Apremilast is labeled as pregnancy category C. Women of reproductive potential should be advised&#x000a0;about the potential risk of pregnancy loss with apremilast. They should be informed of pregnancy planning and prevention. Contraception should be considered prior to initiate apremilast treatment in childbearing females. Lactating and breastfeeding women should also be advised not to receive apremilast. The primary care physician should be aware of the patient's vaccination status, and all immunizations should be up to date before starting treatment. The patient should also be advised that&#x000a0;receiving live vaccinations during treatment with apremilast is not recommended.</p>
        <p>The interprofessional healthcare team should carefully monitor and routinely follow up with patients with severe renal impairment receiving apremilast. Patients with creatinine clearance of less than 30 mL/min should be thoroughly counseled and educated on dosing modifications and the risk of adverse&#x000a0;events.&#x000a0;In&#x000a0;such patients, during&#x000a0;the initial 5-day titration of therapy,&#x000a0;subjects&#x000a0;should be advised to miss their evening dosages and have their daily dosages decreased to 30mg once daily after that. The healthcare team should reconsider subjects who have not shown clinical improvements&#x000a0;or therapeutic benefits over the 16-week period&#x000a0;for&#x000a0;discontinuation&#x000a0;of apremilast. Continuous intercommunication between the PCP and specialists and their patients can help establish a therapeutic alliance when managed with apremilast promoting medication compliance, reducing adverse effects from apremilast, and improving disease outcomes.<xref ref-type="bibr" rid="article-135220.r2">[2]</xref></p>
      </sec>
      <sec id="article-135220.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=135220&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=135220">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/135220/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=135220">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-135220.s11">
        <title>References</title>
        <ref id="article-135220.r1">
          <label>1</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Padda</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Tripp</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <chapter-title>Phosphodiesterase Inhibitors</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">32644702</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135220.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Quiles Tsimaratos</surname>
                <given-names>N</given-names>
              </name>
              <collab>Groupe de recherche sur le psoriasis de la Soci&#x000e9;t&#x000e9; fran&#x000e7;aise de dermatologie</collab>
            </person-group>
            <article-title>[Apremilast].</article-title>
            <source>Ann Dermatol Venereol</source>
            <year>2019</year>
            <season>Jun-Jul</season>
            <volume>146</volume>
            <issue>6-7</issue>
            <fpage>470</fpage>
            <page-range>470-473</page-range>
            <pub-id pub-id-type="pmid">31227297</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135220.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keating</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Apremilast: A Review in Psoriasis and Psoriatic Arthritis.</article-title>
            <source>Drugs</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>77</volume>
            <issue>4</issue>
            <fpage>459</fpage>
            <page-range>459-472</page-range>
            <pub-id pub-id-type="pmid">28213862</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135220.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maloney</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tegtmeyer</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>EY</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Off-label studies on apremilast in dermatology: a review.</article-title>
            <source>J Dermatolog Treat</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>31</volume>
            <issue>2</issue>
            <fpage>131</fpage>
            <page-range>131-140</page-range>
            <pub-id pub-id-type="pmid">30935262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135220.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nassim</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Alajmi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jfri</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pehr</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Apremilast in dermatology: A review of literature.</article-title>
            <source>Dermatol Ther</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>6</issue>
            <fpage>e14261</fpage>
            <pub-id pub-id-type="pmid">32876993</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135220.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moore</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Willoughby</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>The role of cAMP regulation in controlling inflammation.</article-title>
            <source>Clin Exp Immunol</source>
            <year>1995</year>
            <month>Sep</month>
            <volume>101</volume>
            <issue>3</issue>
            <fpage>387</fpage>
            <page-range>387-9</page-range>
            <pub-id pub-id-type="pmid">7664483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135220.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schafer</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Parton</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Capone</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cedzik</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Brady</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Man</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Muller</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Stirling</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Chopra</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.</article-title>
            <source>Cell Signal</source>
            <year>2014</year>
            <month>Sep</month>
            <volume>26</volume>
            <issue>9</issue>
            <fpage>2016</fpage>
            <page-range>2016-29</page-range>
            <pub-id pub-id-type="pmid">24882690</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135220.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Edwards</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Blanco</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Crowley</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Birbara</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Jaworski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Aelion</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Vessey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zhan</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Bird</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3).</article-title>
            <source>Ann Rheum Dis</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>75</volume>
            <issue>6</issue>
            <fpage>1065</fpage>
            <page-range>1065-73</page-range>
            <pub-id pub-id-type="pmid">26792812</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135220.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pinter</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Beigel</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>K&#x000f6;rber</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Homey</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Beissert</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gerdes</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Staubach-Renz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Radtke</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>M&#x000f6;ssner</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>[Gastrointestinal side effects of apremilast : Characterization and management].</article-title>
            <source>Hautarzt</source>
            <year>2019</year>
            <month>May</month>
            <volume>70</volume>
            <issue>5</issue>
            <fpage>354</fpage>
            <page-range>354-362</page-range>
            <pub-id pub-id-type="pmid">30937481</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135220.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kavanaugh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gladman</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Schett</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Guerette</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Delev</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Teng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Paris</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mease</surname>
                <given-names>PJ</given-names>
              </name>
            </person-group>
            <article-title>Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1-3 pooled analysis.</article-title>
            <source>Arthritis Res Ther</source>
            <year>2019</year>
            <month>May</month>
            <day>10</day>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>118</fpage>
            <pub-id pub-id-type="pmid">31077258</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135220.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strober</surname>
                <given-names>BE</given-names>
              </name>
            </person-group>
            <article-title>New Therapies for Psoriasis.</article-title>
            <source>Semin Cutan Med Surg</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>35</volume>
            <issue>4S</issue>
            <fpage>S71</fpage>
            <page-range>S71-S73</page-range>
            <pub-id pub-id-type="pmid">29850660</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135220.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hoffman</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Farhangian</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Psoriasis during pregnancy: characteristics and important management recommendations.</article-title>
            <source>Expert Rev Clin Immunol</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>11</volume>
            <issue>6</issue>
            <fpage>709</fpage>
            <page-range>709-20</page-range>
            <pub-id pub-id-type="pmid">25873365</pub-id>
          </element-citation>
        </ref>
        <ref id="article-135220.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zerilli</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ocheretyaner</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Apremilast (Otezla): A New Oral Treatment for Adults With Psoriasis and Psoriatic Arthritis.</article-title>
            <source>P T</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>40</volume>
            <issue>8</issue>
            <fpage>495</fpage>
            <page-range>495-500</page-range>
            <pub-id pub-id-type="pmid">26236137</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
